{"id":"NCT00516321","sponsor":"GlaxoSmithKline","briefTitle":"Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease","officialTitle":"Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2011-04","completion":"2011-05","firstPosted":"2007-08-15","resultsPosted":"2012-07-30","lastUpdate":"2013-11-05"},"enrollment":687,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"eltrombopag","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[],"summary":"The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR).","primaryOutcome":{"measure":"Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase","timeFrame":"From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)","effectByArm":[{"arm":"Placebo+Antiviral Therapy: DB Phase","deltaMin":33,"sd":null},{"arm":"Eltrombopag+Antiviral Therapy: DB Phase","deltaMin":104,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0064"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":2},"locations":{"siteCount":191,"countries":["United States","Australia","Belgium","Brazil","Canada","Czechia","France","Germany","Hong Kong","India","Israel","Italy","Netherlands","Pakistan","Poland","Puerto Rico","Romania","Russia","Slovakia","South Korea","Spain","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["26173631","25777337","24126097"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":715},"commonTop":["Neutropenia","Anemia","Headache","Fatigue","Pyrexia"]}}